Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Operating Income: 2023-2025

Historic Operating Income for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to -$15.8 million.

  • Compass Therapeutics' Operating Income fell 29.23% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$71.4 million, marking a year-over-year decrease of 28.81%. This contributed to the annual value of -$56.6 million for FY2024, which is 12.43% down from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' Operating Income is -$15.8 million, which was up 24.92% from -$21.1 million recorded in Q2 2025.
  • Compass Therapeutics' Operating Income's 5-year high stood at -$9.7 million during Q1 2023, with a 5-year trough of -$21.1 million in Q2 2025.
  • For the 3-year period, Compass Therapeutics' Operating Income averaged around -$14.7 million, with its median value being -$15.0 million (2024).
  • Data for Compass Therapeutics' Operating Income shows a maximum YoY slumped of 40.69% (in 2025) over the last 5 years.
  • Compass Therapeutics' Operating Income (Quarterly) stood at -$15.4 million in 2023, then decreased by 7.67% to -$16.6 million in 2024, then dropped by 29.23% to -$15.8 million in 2025.
  • Its Operating Income was -$15.8 million in Q3 2025, compared to -$21.1 million in Q2 2025 and -$18.0 million in Q1 2025.